A detailed history of Credit Suisse Ag transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 72,494 shares of KURA stock, worth $648,096. This represents 0.0% of its overall portfolio holdings.

Number of Shares
72,494
Previous 69,202 4.76%
Holding current value
$648,096
Previous $995,000 55.38%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$13.42 - $23.53 $44,178 - $77,460
3,292 Added 4.76%
72,494 $1.55 Million
Q4 2023

Feb 08, 2024

SELL
$7.58 - $14.38 $20,390 - $38,682
-2,690 Reduced 3.74%
69,202 $995,000
Q3 2023

Nov 13, 2023

SELL
$8.44 - $11.86 $65,139 - $91,535
-7,718 Reduced 9.69%
71,892 $655,000
Q2 2023

Aug 11, 2023

BUY
$9.62 - $13.99 $74,131 - $107,806
7,706 Added 10.72%
79,610 $842,000
Q1 2023

May 10, 2023

BUY
$10.71 - $14.6 $73,427 - $100,097
6,856 Added 10.54%
71,904 $879,000
Q4 2022

Feb 13, 2023

BUY
$11.23 - $16.9 $138,005 - $207,684
12,289 Added 23.29%
65,048 $807,000
Q3 2022

Nov 10, 2022

BUY
$12.01 - $19.45 $67,988 - $110,106
5,661 Added 12.02%
52,759 $721,000
Q2 2022

Aug 12, 2022

SELL
$10.71 - $18.33 $38,041 - $65,108
-3,552 Reduced 7.01%
47,098 $863,000
Q1 2022

May 16, 2022

BUY
$11.78 - $16.98 $14,925 - $21,513
1,267 Added 2.57%
50,650 $815,000
Q4 2021

Feb 14, 2022

BUY
$12.22 - $19.57 $72,562 - $116,206
5,938 Added 13.67%
49,383 $692,000
Q3 2021

Nov 12, 2021

SELL
$15.42 - $21.72 $220,228 - $310,205
-14,282 Reduced 24.74%
43,445 $814,000
Q2 2021

Aug 16, 2021

BUY
$20.85 - $29.88 $325,781 - $466,875
15,625 Added 37.11%
57,727 $1.2 Million
Q1 2021

May 14, 2021

SELL
$24.75 - $39.14 $14.9 Million - $23.5 Million
-601,022 Reduced 93.45%
42,102 $1.19 Million
Q4 2020

Feb 12, 2021

BUY
$29.0 - $41.62 $944,646 - $1.36 Million
32,574 Added 5.34%
643,124 $21 Million
Q3 2020

Nov 13, 2020

BUY
$16.3 - $30.64 $8.93 Million - $16.8 Million
547,762 Added 872.4%
610,550 $18.7 Million
Q2 2020

Aug 12, 2020

BUY
$7.95 - $18.81 $374,119 - $885,179
47,059 Added 299.19%
62,788 $1.02 Million
Q1 2020

May 13, 2020

SELL
$6.45 - $14.04 $175,975 - $383,053
-27,283 Reduced 63.43%
15,729 $157,000
Q4 2019

Feb 12, 2020

BUY
$12.97 - $15.94 $266,650 - $327,710
20,559 Added 91.56%
43,012 $591,000
Q3 2019

Nov 12, 2019

BUY
$14.75 - $20.87 $49,722 - $70,352
3,371 Added 17.67%
22,453 $341,000
Q2 2019

Aug 14, 2019

BUY
$14.71 - $19.79 $69,593 - $93,626
4,731 Added 32.97%
19,082 $375,000
Q1 2019

May 14, 2019

BUY
$13.73 - $16.87 $20,842 - $25,608
1,518 Added 11.83%
14,351 $238,000
Q4 2018

Feb 13, 2019

SELL
$10.6 - $17.49 $56,275 - $92,854
-5,309 Reduced 29.26%
12,833 $180,000
Q3 2018

Nov 13, 2018

BUY
$16.65 - $21.85 $81,068 - $106,387
4,869 Added 36.68%
18,142 $318,000
Q2 2018

Aug 14, 2018

BUY
$14.8 - $18.8 $196,440 - $249,532
13,273 New
13,273 $241,000
Q4 2017

Feb 14, 2018

SELL
$13.5 - $16.65 $172,273 - $212,470
-12,761 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$6.05 - $14.95 $77,204 - $190,776
12,761
12,761 $190,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $598M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.